Precision’s PBCAR0191 to Target Autologous CD19 CAR-T Relapsed Patients; PBCAR269A to Be Used with Nirogacestat; ASH 2021 Day 1 Precision Investor Event

On Saturday, December 11, Precision held their investor event (press release / presentation) discussing clinical updates from their CAR-T pipeline at ASH 2021. Celltelligence provides insights on how Precision could leverage the advancement of autologous CD19 CAR-Ts into earlier lines of therapy to target a growing, yet less competitive, patient population.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.